157 related articles for article (PubMed ID: 6157470)
1. Multiple ventricular extrasystoles following administration of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA).
Falkson G
Cancer Treat Rep; 1980; 64(2-3):358. PubMed ID: 6157470
[No Abstract] [Full Text] [Related]
2. Acute ventricular fibrillation and death during infusion of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA).
Von Hoff DD; Elson D; Polk G; Coltman C
Cancer Treat Rep; 1980; 64(2-3):356-8. PubMed ID: 6931630
[No Abstract] [Full Text] [Related]
3. A phase II evaluation of m-AMSA, 4'-(9-acridinylamino) methanesulfon-m-anisidide, in patients with breast cancer.
Currie VE; Howard J; Wittes R
Cancer Clin Trials; 1981; 4(3):249-51. PubMed ID: 6895189
[TBL] [Abstract][Full Text] [Related]
4. Neurologic and cardiac rhythm abnormalities associated with 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) therapy.
Legha SS; Latreille J; McCredie KB; Bodey GP
Cancer Treat Rep; 1979; 63(11-12):2001-3. PubMed ID: 526933
[No Abstract] [Full Text] [Related]
5. Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with advanced colorectal carcinoma.
Carroll DS; Kemeny N; Lynch G; Wookcock T
Cancer Treat Rep; 1980; 64(10-11):1149-50. PubMed ID: 6893951
[No Abstract] [Full Text] [Related]
6. Phase II. Evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with advanced sarcoma.
Sordillo PP; Magill GB; Gralla RJ; Golbey RB
Cancer Treat Rep; 1980; 64(10-11):1129-30. PubMed ID: 6893950
[No Abstract] [Full Text] [Related]
7. Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic renal cell carcinoma.
Van Echo DA; Markus S; Aisner J; Wiernik PH
Cancer Treat Rep; 1980; 64(8-9):1009-10. PubMed ID: 6893810
[No Abstract] [Full Text] [Related]
8. Phase II. Trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in the treatment of advanced non-Hodgkin's lymphoma.
Warrell RP; Straus DJ; Young CW
Cancer Treat Rep; 1980; 64(10-11):1157-8. PubMed ID: 6893952
[TBL] [Abstract][Full Text] [Related]
9. Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly iv dose schedule.
Woodcock TM; Schneider RJ; Young CW
Cancer Treat Rep; 1980 Jan; 64(1):53-5. PubMed ID: 6892893
[TBL] [Abstract][Full Text] [Related]
10. Phase II evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with non-small cell lung cancer.
Casper ES; Gralla RJ; Kelsen DP; Natale RB; Sordillo P; Houghton A
Cancer Treat Rep; 1980; 64(2-3):345-7. PubMed ID: 6893294
[No Abstract] [Full Text] [Related]
11. Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma.
Legha SS; Hall SW; Powell KC; Burgess MA; Benjamin RS; Gutterman JU; Bodey GP
Cancer Clin Trials; 1980; 3(2):111-4. PubMed ID: 6893573
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic hypernephroma.
Schneider RJ; Woodcock TM; Yagoda A
Cancer Treat Rep; 1980 Jan; 64(1):183-5. PubMed ID: 6892892
[No Abstract] [Full Text] [Related]
13. Ventricular fibrillation following AMSA. Uncomplicated retreatment following correction of hypokalemia.
McLaughlin P; Salvador PG; Cabanillas F; Legha SS
Cancer; 1983 Aug; 52(3):557-8. PubMed ID: 6688037
[TBL] [Abstract][Full Text] [Related]
14. Phase I-II study of m-AMSA administered as a continuous infusion.
Micetich KC; Zwelling LA; Gormley P; Young RC
Cancer Treat Rep; 1982 Oct; 66(10):1813-7. PubMed ID: 6897013
[TBL] [Abstract][Full Text] [Related]
15. Phase II evaluation of m-AMSA (4'-(9-acridinylamino)-methanesulfon-m-anisidide) in patients with adenocarcinoma of the pancreas.
Sternberg CN; Magill GB; Sordillo PP; Cheng E; Currie VE
Am J Clin Oncol; 1983 Aug; 6(4):459-62. PubMed ID: 6688151
[TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA) in patients with gastric adenocarcinoma.
Sordillo PP; Magill GB; Gralla RJ; Kelsen DP
Am J Clin Oncol; 1982 Jun; 5(3):273-5. PubMed ID: 6896259
[TBL] [Abstract][Full Text] [Related]
17. [Case of refractory acute myeloblastic leukemia who achieved complete remission by a new anti-leukemic agent, 4'-(9-acridinylamino) methanesulfon-m-anisidide (AMSA)].
Nagura E; Kawashima K; Suzuki H; Ohno R; Yamada K; Yokomaku S; Ogawa M
Rinsho Ketsueki; 1983 May; 24(5):632-8. PubMed ID: 6577212
[No Abstract] [Full Text] [Related]
18. 4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia.
Kahn SB; Sklaroff R; Lebedda J; Conroy JF; Bulova S; Brodsky I
Am J Clin Oncol; 1983 Aug; 6(4):493-502. PubMed ID: 6191561
[TBL] [Abstract][Full Text] [Related]
19. Phase II clinical evaluation of intravenous 4'-(9-acridinylamino)methanesulfon-m-anisidide in colorectal cancer.
Valdivieso M; Stroehlein JR; Bedikian AY; Karlin DA; Legha SS; Bennetts RW; Bodey GP
Am J Clin Oncol; 1983 Feb; 6(1):39-44. PubMed ID: 6687657
[TBL] [Abstract][Full Text] [Related]
20. Drug sensitivity and cross-resistance of the 4'-(9-acridinylamino)methanesulfon-m-anisidide-resistant subline of HL-60 human leukemia.
Odaimi M; Andersson BS; McCredie KB; Beran M
Cancer Res; 1986 Jul; 46(7):3330-3. PubMed ID: 3754787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
